| Literature DB >> 36009694 |
Rute Canejo-Teixeira1,2, Ana Lima1, Ana Santana1,2,3,4.
Abstract
Contrast-enhanced ultrasound (CEUS) is an emerging technology in veterinary medicine involving the administration of intravenous contrast agents, and it is increasingly recognized for its high potential as a diagnostic imaging tool for small animals. This exam is easy and quick to perform, safe and reliable, and allows for the differentiation of lesions. It permits the identification of lesions that may require more invasive procedures, from those that can be safely dismissed to those that can be followed-up with ultrasound imaging. Although it has been extensively reviewed for use in human medicine, there is an overall lack of information about the application of this technique for cats and dogs, particularly in splenic studies, which can be particularly important for small animals. The present review describes and summarizes the CEUS applications used for splenic analysis in cats and dogs, providing a basic overview of CEUS technology with examples of common and uncommon features of focal splenic lesions. It also systematically gathers the results obtained for benign and malignant splenic lesions described in the literature, whilst providing guidelines for their interpretation. Furthermore, it presents the advantages of using CEUS for splenic analysis in cats and dogs and the main factors that may influence the quality of the imaging and the accuracy of the diagnosis. This type of knowledge can be used to provide a framework to help veterinarians make informed decisions regarding the use of this emerging technique for splenic lesions, guiding their interpretation of CEUS findings in the splenic ultrasounds of cats and dogs.Entities:
Keywords: contrast-enhanced ultrasound; dogs and cats; spleen
Year: 2022 PMID: 36009694 PMCID: PMC9404716 DOI: 10.3390/ani12162104
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Figure 1Schematic representation of the CEUS method. A contrast agent is administered as an intravenous injection. The dilution of the contrast agent in the organ of interest is detected downstream by ultrasound imaging. AUC = area under the curve; TA = appearance time; TTP = time to peak; WIT = wash-in time; WOT = wash-out time. Note: parameters may vary depending on the software in use.
Figure 2Advantages of CEUS as a diagnostic tool.
Summary of CEUS findings in benign splenic lesions.
| Diagnosis of Malignancy | Diagnostic Procedure | n | Age (Mean) | Species | Sex | CEUS Findings | Contrast Medium | Stats. | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Nodular hyperplasia | Cytology * | 20 | * | D | * | Isoechoic wash-in, hypoechoic peak enhancement, and anechoic wash-out | Sulphur hexafluoride | CI 95% * | [ |
| Nodular hyperplasia, | One or a combination of cytology and histopathology * | 7 | 10.1 yrs | D | M/F * | Variations in all phases *; no tortuous vessels seen | Sulfur hexafluoride | Sensitivity, specificity, and accuracy | [ |
| extramedullary hematopoiesis, | 4 | ||||||||
| one reactive lymphoid tissue | 1 | ||||||||
| Nodular hyperplasia | Histopathology (6) and cytology (2) | 8 | 8.5 yrs | D | M (5), F (3) | Isoechoic vascular and hypoechoic parenchymal phases | Perflubutane | 2-tailed Fisher’s exact test, sensitivity, and specificity with 95% CI | [ |
| Hematoma | Histopathology | 2 | 10.5 yrs | D | M (1), F (1) | Heteroechoic vascular and hypoechoic parenchymal | |||
| Extramedullary hematopoiesis | Histopathology | 2 | 9.5 yrs | D | M (2) | Isoechoic vascular and hetero-isoechoic parenchymal | |||
| Granuloma | Histopathology | 1 | 10 | D | M (1) | Isoechoic vascular and hypoechoic parenchymal | |||
| Hematoma | Histopathology | 5 | 10.6 yrs | D | M, F * | Not able to differentiate from hematomas | Perfluoropropane | Unpaired 2-tailed | [ |
| Hematoma with hyperplasia | 2 | ||||||||
| Nodular hyperplasia | Histopathology and cytology * | 6 | 10 yrs | D, C * | M, F * | Isoechoic in all phases without tortuous vessels | Sulfur hexafluoride | None reported | [ |
| Extramedullary hematopoiesis | 2 | ||||||||
| Hematoma | 1 | Hypoechoic in all phases | |||||||
| Benign fibrous histiocytoma | 1 | Hyperechoic in all phases with dense vessels | |||||||
| Accessory spleen (splanunculus) | 1 | Isoechoic | |||||||
| Reactive hyperplasia | Histopathology and cytology * | 8 | 9.6 yrs | D | M, F * | Isoechoic and hyperechoic in wash-in and peak enhancement and variable in wash-out | Sulphur hexafluoride | Fisher’s exact test and odds ratios with 95% CI | [ |
| Nodular hyperplasia | 10 | Variable in all phases | |||||||
| Extramedullary hematopoiesis | 6 | Generally isoechoic in all phases | |||||||
| Hematoma | 3 | Hypoechoic and hyperechoic in all phases | |||||||
| Leishmaniosis (normal spleen) | Cytology | 22 | 4.9 yrs | D | M, F * | Variable in all phases, depending on architecture of the spleen, and no difference in quantitative measurements were found | Sulphur hexafluoride | ANOVA | [ |
* details unspecified by authors; yrs = years, D = dog, C = cat, M = male, F = female, CI = confidence interval.
Summary of CEUS findings in malignant splenic lesions.
| Diagnosis of Malignancy | Diagnostic Procedure | n | Age (m) | Species | Sex | CEUS Findings | Contrast Medium | Stats. | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Focal histiocytic sarcomas | One or combination of cytology and histopathology * | 2 | 10.1 yrs | D | M/F | Hypoenhanced in parenchymal phase; tortuous vessels in all phases | Sulfur hexafluoride | Sensitivity, specificity, and accuracy | [ |
| Hemagiosarocoma | 3 | ||||||||
| Hemagiosarocoma | Histopathology | 8 | 12 yrs | D | M (3), F (5) | Hypoenhanced in late vascular phase | Perflubutane | 2-tailed Fisher’s exact test, sensitivity, and specificity with 95% CI | [ |
| Lymphoma | Cytology | 3 | 5 yrs | D | M (1), F (2) | ||||
| Histiocyticsarcoma | Histopathology | 2 | 9.5 yrs | D | M (1), F (1) | ||||
| Leiomyosarcoma | Histopathology | 1 | 14 yrs | D | F (1) | ||||
| Osteosarcoma | Histopathology | 1 | 12 yrs | D | F (1) | ||||
| Carcinoma | Histopathology | 1 | 11 yrs | D | F (1) | ||||
| Lymphosarcoma | Histopathology and cytology * | 7 | 10 yrs | D, C * | M, F * | Hypoechoic in wash-out phase (late vascular phase) | Sulfur hexafluoride | None reported | [ |
| Hemangiosarcoma | 4 | ||||||||
| Malignant fibrous histiocytoma | 2 | ||||||||
| Undifferentiated sarcoma | 1 | ||||||||
| Histiocytic sarcoma | 1 | ||||||||
| liposarcoma | 1 | ||||||||
| Mast cell tumour | 1 | ||||||||
| Metastasis * | 1 | ||||||||
| Hemangiosarcoma | Histopathology | 11 | 10.6 yrs | D | M, F * | Not able to differentiate from hematomas | Perfluoropropane | Unpaired 2-tailed | [ |
| Hemangiosarcoma | Histopathology and cytology * | 10 | 9.6 yrs | D | M, F * | Hypoenhancement in wash-in and peak enhancement and wash-out phase | Sulphur hexafluoride | Fisher’s exact test and odds ratios with 95% CI | [ |
| Malignant lymphoma | 6 | ||||||||
| Malignant histiocytosis | 5 | ||||||||
| Malignant fibrous histiocytoma | 1 | ||||||||
| Mesenchymal neoplasia | 3 | ||||||||
| Mast cell tumour | 2 | ||||||||
| Pancreatic adenocarcinoma metastasis | 1 | ||||||||
| Plasmocytoma | 1 |
* details unspecified by authors; yrs = years, D = dog, C = cat, M = male, F = female, CI = confidence interval.
Figure 3Guidelines for the CEUS data interpretation of splenic masses in cats and dogs: the relationship between the data obtained in CEUS and the type of splenic mass detected.
Figure 4Guidelines for the CEUS data interpretation of splenic masses in cats and dogs: the expected diagnosis for benign and malignant splenic masses according to the data obtained in the CEUS examination.
Figure 5Factors that can influence the quality of a CEUS analysis in veterinary applications.